Definium Therapeutics, Inc. (NASDAQ:DFTX) Receives Consensus Recommendation of "Buy" from Analysts

Key Points

• Analysts consensus: Fifteen brokerages rate Definium Therapeutics (DFTX) a "Buy" (1 sell, 11 buy, 3 strong buy) with an average 12‑month price target of $38.00, and several firms recently raised targets (e.g., HC Wainwright to $70).
• Company profile: Definium is a clinical‑stage biopharmaceutical firm (formerly MindMed as of Jan 2026) advancing lead candidates MM120 in Phase 3 for generalized anxiety disorder and ADHD and DT402 in Phase 2a for core autism symptoms.
• Market snapshot: Shares opened at $20.49 with a market cap of $2.04B and a 12‑month range of $6.03–$26.25; the company shows high liquidity (current/quick ratio 6.29) but a negative PE (−9.62), reflecting no earnings.

Shares of Definium Therapeutics, Inc. (NASDAQ:DFTX - Get Free Report) have been given a consensus rating of "Buy" by the fifteen brokerages that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, eleven have given a buy recommendation and three have issued a strong buy recommendation on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $38.00.

A number of equities analysts have recently issued reports on the stock. Wolfe Research assumed coverage on shares of Definium Therapeutics in a research report on Monday, February 23rd. They set an "outperform" rating and a $25.00 target price on the stock. Canaccord Genuity Group set a $38.00 target price on shares of Definium Therapeutics and gave the stock a "buy" rating in a research report on Thursday, April 16th. HC Wainwright lifted their price objective on shares of Definium Therapeutics from $55.00 to $70.00 and gave the company a "buy" rating in a research report on Monday, March 2nd. Leerink Partners lifted their price objective on shares of Definium Therapeutics from $23.00 to $30.00 and gave the company an "outperform" rating in a research report on Wednesday, April 22nd. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Definium Therapeutics in a research report on Monday, February 2nd.

Hedge Funds Weigh In On Definium Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of DFTX. Royal Bank of Canada grew its position in Definium Therapeutics by 10.4% in the 1st quarter. Royal Bank of Canada now owns 65,237 shares of the company's stock valued at $382,000 after buying an additional 6,148 shares during the last quarter. Creative Planning grew its position in Definium Therapeutics by 2.6% in the 2nd quarter. Creative Planning now owns 66,097 shares of the company's stock valued at $429,000 after buying an additional 1,655 shares during the last quarter. JPMorgan Chase & Co. grew its position in Definium Therapeutics by 5.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 48,487 shares of the company's stock valued at $315,000 after buying an additional 2,342 shares during the last quarter. Rhumbline Advisers grew its position in Definium Therapeutics by 6.3% in the 2nd quarter. Rhumbline Advisers now owns 115,296 shares of the company's stock valued at $748,000 after buying an additional 6,839 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its position in Definium Therapeutics by 110.4% in the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company's stock valued at $25,000 after buying an additional 2,003 shares during the last quarter. 27.91% of the stock is currently owned by hedge funds and other institutional investors.

Definium Therapeutics Stock Performance

Shares of DFTX opened at $20.49 on Thursday. The company has a current ratio of 6.29, a quick ratio of 6.29 and a debt-to-equity ratio of 0.12. The firm has a market cap of $2.04 billion, a PE ratio of -9.62 and a beta of 2.44. The company's 50 day simple moving average is $19.53 and its 200-day simple moving average is $15.74. Definium Therapeutics has a 12-month low of $6.03 and a 12-month high of $26.25.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.